{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:42:44Z","timestamp":1777916564684,"version":"3.51.4"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0232773","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T17:45:42Z","timestamp":1588700742000},"page":"e0232773","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Treatment and re-treatment results of HCV patients in the DAA era"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2781-5088","authenticated-orcid":true,"given":"Felix","family":"Piecha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Michael","family":"G\u00e4n\u00dfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Kathrin","family":"Ozga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte H.","family":"Wehmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Kluwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena","family":"Laschtowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-5174","authenticated-orcid":true,"given":"Johann","family":"von Felden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Sterneck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Pischke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansgar W.","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Schulze zur Wiesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"pone.0232773.ref001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-230X-14-87","article-title":"Safety and efficacy of protease inhibitor based combination therapy in a single-center \"real-life\" cohort of 110 patients with chronic hepatitis C genotype 1 infection","volume":"14","author":"MH Wehmeyer","year":"2014","journal-title":"BMC gastroenterol"},{"issue":"9","key":"pone.0232773.ref002","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/apt.14592","article-title":"High efficacy of sofosbuvir\/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection","volume":"47","author":"J von Felden","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0232773.ref003","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-life effectiveness and safety of Glecaprevir\/Pibrentasvir in 723 patients with chronic hepatitis C","volume":"70","author":"R D'Ambrosio","year":"2019","journal-title":"J hepatol"},{"key":"pone.0232773.ref004","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/jvh.13218","article-title":"Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment","volume":"27","author":"KE Daniel","year":"2020","journal-title":"J Viral Hepat"},{"issue":"6","key":"pone.0232773.ref005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.28491","article-title":"Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen","volume":"63","author":"C Hezode","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"pone.0232773.ref006","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.13887","article-title":"Letter: retreatment of patients with chronic hepatitis C who have failed interferon-free combination therapy with direct acting anti-virals","volume":"45","author":"K Kozbial","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"pone.0232773.ref007","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/cid\/cix916","article-title":"Retreatment With Sofosbuvir Plus Grazoprevir\/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study","volume":"66","author":"V de Ledinghen","year":"2018","journal-title":"Clin infect dis"},{"issue":"10207","key":"pone.0232773.ref008","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"CW Spearman","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"pone.0232773.ref009","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","year":"2018","journal-title":"J hepatol"},{"issue":"22","key":"pone.0232773.ref010","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"M Bourliere","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0232773.ref011","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00535-019-01575-9","article-title":"Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1\/2\/3 infections","volume":"54","author":"H Sezaki","year":"2019","journal-title":"J gastroenterol"},{"key":"pone.0232773.ref012","first-page":"49","article-title":"Liver stiffness: a novel parameter for the diagnosis of liver disease Hepatic Medicine","volume":"2","author":"S Mueller","year":"2010","journal-title":"Evidence and Research"},{"issue":"4","key":"pone.0232773.ref013","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1053\/j.gastro.2008.01.034","article-title":"Performance of transient elastography for the staging of liver fibrosis: a meta-analysis","volume":"134","author":"M Friedrich-Rust","year":"2008","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0232773.ref014","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals","volume":"154","author":"J Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"pone.0232773.ref015","article-title":"Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1\u20133 Infections","author":"J Dietz","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"pone.0232773.ref016","doi-asserted-by":"crossref","first-page":"e0134395","DOI":"10.1371\/journal.pone.0134395","article-title":"Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients","volume":"10","author":"J Dietz","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"pone.0232773.ref017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jhep.2017.02.027","article-title":"Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma","volume":"67","author":"LA Beste","year":"2017","journal-title":"J hepatol"},{"issue":"1","key":"pone.0232773.ref018","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s12879-018-3465-2","article-title":"The efficacy of paritaprevir\/ritonavir\/ombitasvir+dasabuvir and ledipasvir\/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors\u2014a multicenter cohort study","volume":"18","author":"E Janczewska","year":"2018","journal-title":"BMC infect dis"},{"issue":"3","key":"pone.0232773.ref019","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","article-title":"Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent","volume":"63","author":"X Forns","year":"2015","journal-title":"J hepatol"},{"issue":"10","key":"pone.0232773.ref020","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/apt.14604","article-title":"Safety and efficacy of ledipasvir\/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir\/sofosbuvir","volume":"47","author":"AA Modi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"pone.0232773.ref021","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jhep.2017.08.012","article-title":"\"Empirical\" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen","volume":"67","author":"L Kramer","year":"2017","journal-title":"J hepatol"},{"issue":"9","key":"pone.0232773.ref022","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/17474124.2019.1651642","article-title":"Management of HCV patients in cases of direct-acting antiviral failure","volume":"13","author":"CN Hayes","year":"2019","journal-title":"Expert rev gastroenterol hepatol"},{"issue":"12","key":"pone.0232773.ref023","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/17474124.2018.1541237","article-title":"Direct acting antivirals failure: cause and retreatment options","volume":"12","author":"L Parlati","year":"2018","journal-title":"Expert rev gastroenterol hepatol"},{"key":"pone.0232773.ref024","article-title":"Efficacy of retreatment after failed direct-acting antiviral therapy in patients with HCV Genotype 1\u20133 infections","author":"J Dietz","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"pone.0232773.ref025","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/hep4.1337","article-title":"Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct-Acting Antiviral Treatment Failure in Patients With Hepatitis C?","volume":"3","author":"F Piecha","year":"2019","journal-title":"Hepatol commun"},{"issue":"1","key":"pone.0232773.ref026","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12916-018-1162-z","article-title":"Pathways to ensure universal and affordable access to hepatitis C treatment","volume":"16","author":"CH Douglass","year":"2018","journal-title":"BMC med"},{"issue":"10123","key":"pone.0232773.ref027","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(18)30462-8","article-title":"Tackling hepatitis C-Pakistan's road to success","volume":"391","author":"A Moin","year":"2018","journal-title":"Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0232773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T17:46:00Z","timestamp":1588700760000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0232773"}},"subtitle":[],"editor":[{"given":"Jason","family":"Blackard","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0232773","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]}}}